ClinicalTrials.gg
CompletedNCT01070784Updated Apr 29, 2014Results posted

A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan

A Phase 3 interventional study of Symbicort Turbuhaler (Budesonide/formoterol) and Drug: any available COPD treatment; investigator to decide in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 17 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-04-29.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
73rd of 194
328 · median 137
Started
2010
with 24 others
Phase 3
76 of 284
4 open now
Registered
66th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 73rd largest by enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2010, is one of 76 in phase 3, and was the 66th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of Symbicort Turbuhaler compared to standard COPD treatment during one year in Japanese patients with COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Symbicort
  • Safety
  • Efficacy
  • COPD
  • Japanese
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A current clinical diagnosis of according to the guidelines (GOLD, JPS)
  • Documented COPD symptoms for more than 2 years
  • Pre-bronchodilator ≦50% of predicted normal value, and post-bronchodilator FEV1/FVC\<70%

Exclusion criteria

Exclusion Criteria:

  • History and/or current clinical diagnosis of asthma and atopic diseases such as allergic rhinitis
  • Subjects with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator
  • exacerbation during the run-in period or within 4 weeks prior to registration, requiring hospitalization and/or treatment with systemic .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    1

    Drug: Symbicort Turbuhaler (Budesonide/formoterol)

  • Active comparator
    2

    Drug: Drug: any available COPD treatment; investigator to decide

Interventions

  • DrugSymbicort Turbuhaler (Budesonide/formoterol)

    Drug page: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

    2 x 160/4.5 microgram, inhalation, bid, 52 weeks

    Also known as: Symbicort Turbuhaler

  • DrugDrug: any available COPD treatment; investigator to decide

    According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision

06

What researchers measure

Primary outcomes

  1. Clinical Laboratory Test: Haematology -Erythrocytes

    Mean change from Baseline

    Time frame: Baseline and 52 week after

  2. Clinical Laboratory Test: Haematology -Haemoglobin

    Change from baseline

    Time frame: Baseline and 52 week after

  3. Clinical Laboratory Test: Haematology -Leucocytes

    Change from baseline

    Time frame: Baseline and 52 week after

  4. Clinical Laboratory Test: Haematology -Platelet Count

    Change from baseline

    Time frame: Baseline and 52 week after

  5. Clinical Laboratory Test: Haematology -Eosinophils

    Change from baseline

    Time frame: Baseline and 52 week after

  6. Clinical Laboratory Test: Haematology -Basophils

    Change from baseline

    Time frame: Baseline and 52 week after

  7. Clinical Laboratory Test: Haematology -Lymphocytes

    Change from baseline

    Time frame: Baseline and 52 week after

  8. Clinical Laboratory Test: Haematology -Monocytes

    Change from baseline

    Time frame: Baseline and 52 week after

  9. Clinical Laboratory Test: Haematology -Neutrophils

    Change from baseline

    Time frame: Baseline and 52 week after

  10. Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase

    Change from baseline

    Time frame: Baseline and 52 week after

  11. Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase

    Change from baseline

    Time frame: Baseline and 52 week after

  12. Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)

    Change from baseline

    Time frame: Baseline and 52 week after

  13. Clinical Laboratory Test: Clinical Chemistry- S-Creatinine

    Change from baseline

    Time frame: Baseline and 52 week after

  14. Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin

    Change from baseline

    Time frame: Baseline and 52 week after

  15. Clinical Laboratory Test: Clinical Chemistry- S-Sodium

    Change from baseline

    Time frame: Baseline and 52 week after

  16. Clinical Laboratory Test: Clinical Chemistry- S-Potassium

    Change from baseline

    Time frame: Baseline and 52 week after

  17. Clinical Laboratory Test: Clinical Chemistry- S- Calcium

    Change from baseline

    Time frame: Baseline and 52 week after

  18. Clinical Laboratory Test: Clinical Chemistry- S-Albumin

    Change from baseline

    Time frame: Baseline and 52 week after

  19. Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total

    Change from baseline

    Time frame: Baseline and 52 week after

  20. Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein

    Change from baseline

    Time frame: Baseline and 52 week after

  21. Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen

    Change from baseline

    Time frame: Baseline and 52 week after

  22. Vital Signs- Sitting Systolic Blood Pressure(SBP)

    Change from baseline

    Time frame: Baseline and 52 week after

  23. Vital Signs- Sitting Diastolic Blood Pressure(DBP)

    Change from baseline

    Time frame: Baseline and 52 week after

  24. Vital Signs- Pulse Rate

    Change from baseline

    Time frame: Baseline and 52 week after

  25. ECG Variables - Heart Rate

    Change from baseline

    Time frame: Baseline and 52 week after

  26. ECG Variables - QT Interval

    Change from baseline

    Time frame: Baseline and 52 week after

  27. ECG Variables - QTcB Interval

    Change from baseline

    Time frame: Baseline and 52 week after

  28. ECG Variables - QTcF Interval

    Change from baseline

    Time frame: Baseline and 52 week after

  29. ECG Variables - RR Interval

    Change from baseline

    Time frame: Baseline and 52 week after

Secondary outcomes

  1. Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening

    There are 5 alternatives (scored 0 to 4, 0= no awakening and 4 =did not sleep at all). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 52-week randomization treatment

  2. Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness

    There are 5 alternatives (scored 0 to 4, 0= unaware of any difficulty and 4 =almost constant, present even when resting). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 52-week randomization treatment

  3. Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough

    There are 5 alternatives (scored 0 to 4, 0= unaware of coughing, 4= never free of cough or need to cough). The change from Run-in period average to Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily during 52-week randomization treatment

  4. Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic

    The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.

    Time frame: Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization

  5. Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic

    The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.

    Time frame: Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization

  6. Time to First COPD Exacerbation

    A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.

    Time frame: Daily during 52-week randomization treatment

  7. Number of COPD Exacerbations Over the Study Treatment Period

    A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment

    Time frame: Daily during 52-week randomization treatment

  8. Rescue Medication Use

    The change from run-in period and daily during 52-week randomization treatment

    Time frame: Daily during 52-week randomization treatment

  9. Health Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ)

    The change from run-in period and daily during 52-week randomization treatment average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).

    Time frame: Daily during run-in period and daily 52-week randomization treatment

  10. Morning Peak Expiratory Flow (PEF) Measured at Home

    The change from Run-in period average to 52-week randomization Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily 52-week randomization treatment

  11. Evening Peak Expiratory Flow (PEF) Measured at Home

    The change from Run-in period average to 52-week randomization Treatment period average for each treatment group

    Time frame: Daily during run-in period and daily 52-week randomization treatment

  12. Morning FEV1 Measured by the Subjects at Home

    The change from run-in period and daily during 52-week randomization treatment

    Time frame: Daily during run-in period and daily 52-week randomization treatment

  13. Evening FEV1 Measured by the Subjects at Home

    The change from run-in period and daily during 52-week randomization treatment

    Time frame: Daily during run-in period and daily 52-week randomization treatment

07

Results

Posted Dec 5, 2013

Participant flow

The first participant entered the study on 28 January 2010, and the last participant completed the study on 24 October 2011. A total of 328 participants were enrolled at 60 centres in Japan, and 260 participants who fulfilled the randomisation criteria were randomised.

Participant flow — Overall Study
MilestoneSymbicort TurbuhalerCOPD Standard Therapy
Started130130
Completed110112
Not completed2018
Withdrew: Withdrawal by subject69
Withdrew: Adverse event149

Outcome measures

PrimaryClinical Laboratory Test: Haematology -Erythrocytes

Mean change from Baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · *10000/μl
Clinical Laboratory Test: Haematology -Erythrocytes
*10000/μlArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Erythrocytes-7.6 ± 23.9-0.1 ± 22.9
PrimaryClinical Laboratory Test: Haematology -Haemoglobin

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · g/dL
Clinical Laboratory Test: Haematology -Haemoglobin
g/dLArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Haemoglobin-0.22 ± 0.74-0.05 ± 0.75
PrimaryClinical Laboratory Test: Haematology -Leucocytes

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · /microliter(mcl)
Clinical Laboratory Test: Haematology -Leucocytes
/microliter(mcl)Arm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Leucocytes160.8 ± 1704.0-184.8 ± 1238.2
PrimaryClinical Laboratory Test: Haematology -Platelet Count

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · *10000/μl
Clinical Laboratory Test: Haematology -Platelet Count
*10000/μlArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Platelet Count0.86 ± 3.030.12 ± 4.04
PrimaryClinical Laboratory Test: Haematology -Eosinophils

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · percentage of Eosinophils
Clinical Laboratory Test: Haematology -Eosinophils
percentage of EosinophilsArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Eosinophils-0.52 ± 2.680.14 ± 1.91
PrimaryClinical Laboratory Test: Haematology -Basophils

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · percentage of Basophils
Clinical Laboratory Test: Haematology -Basophils
percentage of BasophilsArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Basophils-0.06 ± 0.37-0.06 ± 0.35
PrimaryClinical Laboratory Test: Haematology -Lymphocytes

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · percentage of Lymphocytes
Clinical Laboratory Test: Haematology -Lymphocytes
percentage of LymphocytesArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Lymphocytes-5.47 ± 6.56-3.24 ± 7.00
PrimaryClinical Laboratory Test: Haematology -Monocytes

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · percentage of Monocytes
Clinical Laboratory Test: Haematology -Monocytes
percentage of MonocytesArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Monocytes0.29 ± 1.41-0.03 ± 1.35
PrimaryClinical Laboratory Test: Haematology -Neutrophils

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · percentage of Neutrophils
Clinical Laboratory Test: Haematology -Neutrophils
percentage of NeutrophilsArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Haematology -Neutrophils5.78 ± 7.162.92 ± 7.64
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · U/L
Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase
U/LArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase0.5 ± 7.61.5 ± 6.6
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · U/L
Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase
U/LArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase0.0 ± 7.61.1 ± 6.5
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · U/L
Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)
U/LArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)1.3 ± 38.48.2 ± 45.9
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Creatinine

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mg/dL
Clinical Laboratory Test: Clinical Chemistry- S-Creatinine
mg/dLArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Creatinine0.003 ± 0.106-0.017 ± 0.091
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mg/dL
Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin
mg/dLArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin0.05 ± 0.250.00 ± 0.18
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Sodium

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mEq/L
Clinical Laboratory Test: Clinical Chemistry- S-Sodium
mEq/LArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Sodium-0.8 ± 2.0-0.6 ± 1.7
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Potassium

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mEq/L
Clinical Laboratory Test: Clinical Chemistry- S-Potassium
mEq/LArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Potassium-0.11 ± 0.34-0.08 ± 0.37
PrimaryClinical Laboratory Test: Clinical Chemistry- S- Calcium

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mg/dL
Clinical Laboratory Test: Clinical Chemistry- S- Calcium
mg/dLArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S- Calcium0.02 ± 0.340.01 ± 0.33
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Albumin

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · g/dL
Clinical Laboratory Test: Clinical Chemistry- S-Albumin
g/dLArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Albumin0.03 ± 0.240.04 ± 0.26
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Protein, Total

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · g/dL
Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total
g/dLArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total0.01 ± 0.350.02 ± 0.37
PrimaryClinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mg/dL
Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein
mg/dLArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein0.243 ± 1.2910.224 ± 1.423
PrimaryClinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mg/dL
Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen
mg/dLArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen-0.51 ± 4.09-0.64 ± 3.32
PrimaryVital Signs- Sitting Systolic Blood Pressure(SBP)

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mmHg
Vital Signs- Sitting Systolic Blood Pressure(SBP)
mmHgArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Vital Signs- Sitting Systolic Blood Pressure(SBP)-0.8 ± 16.2-3.2 ± 15.0
PrimaryVital Signs- Sitting Diastolic Blood Pressure(DBP)

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · mmHg
Vital Signs- Sitting Diastolic Blood Pressure(DBP)
mmHgArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Vital Signs- Sitting Diastolic Blood Pressure(DBP)-0.8 ± 11.2-1.3 ± 10.7
PrimaryVital Signs- Pulse Rate

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · beats/minute
Vital Signs- Pulse Rate
beats/minuteArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Vital Signs- Pulse Rate3.2 ± 11.13.1 ± 11.5
PrimaryECG Variables - Heart Rate

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · beats/minute
ECG Variables - Heart Rate
beats/minuteArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
ECG Variables - Heart Rate3.6 ± 11.43.4 ± 10.9
PrimaryECG Variables - QT Interval

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · ms
ECG Variables - QT Interval
msArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
ECG Variables - QT Interval-4.5 ± 23.1-7.5 ± 21.2
PrimaryECG Variables - QTcB Interval

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · ms
ECG Variables - QTcB Interval
msArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
ECG Variables - QTcB Interval3.6 ± 20.92.4 ± 22.6
PrimaryECG Variables - QTcF Interval

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · ms
ECG Variables - QTcF Interval
msArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
ECG Variables - QTcF Interval0.7 ± 16.3-1.1 ± 17.4
PrimaryECG Variables - RR Interval

Change from baseline

Time frame:
Baseline and 52 week after
Reported as:
Mean · ms
ECG Variables - RR Interval
msArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
ECG Variables - RR Interval-30.9 ± 121.4-43.8 ± 115.1
SecondaryChronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening

There are 5 alternatives (scored 0 to 4, 0= no awakening and 4 =did not sleep at all). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 52-week randomization treatment
Reported as:
Mean · units on a scale
Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening
units on a scaleArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening0.0 ± 0.5-0.1 ± 0.4
SecondaryChronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness

There are 5 alternatives (scored 0 to 4, 0= unaware of any difficulty and 4 =almost constant, present even when resting). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 52-week randomization treatment
Reported as:
Mean · units on a scale
Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness
units on a scaleArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness-0.2 ± 0.7-0.1 ± 0.7
SecondaryChronic Obstructive Pulmonary Disease (COPD) symptoms_cough

There are 5 alternatives (scored 0 to 4, 0= unaware of coughing, 4= never free of cough or need to cough). The change from Run-in period average to Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily during 52-week randomization treatment
Reported as:
Mean · units on a scale
Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough
units on a scaleArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough-0.2 ± 0.7-0.2 ± 0.7
SecondaryForced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic

The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.

Time frame:
Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization
Reported as:
Geometric mean · percentage of Baseline
Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic
percentage of BaselineArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic104.25 (60.8 to 182.9)98.43 (35.8 to 168.2)
SecondaryForced Vital Capacity (FVC) Measured With the Spirometer at the Clinic

The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.

Time frame:
Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization
Reported as:
Geometric mean · percentage of Baseline
Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic
percentage of BaselineArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic102.51 (77.8 to 141.5)100.04 (67.6 to 158.2)
SecondaryTime to First COPD Exacerbation

A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.

Time frame:
Daily during 52-week randomization treatment
Reported as:
Number · Percentage of participants
Time to First COPD Exacerbation
Percentage of participantsArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Time to First COPD Exacerbation20.031.5
SecondaryNumber of COPD Exacerbations Over the Study Treatment Period

A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment

Time frame:
Daily during 52-week randomization treatment
Reported as:
Number · event
Number of COPD Exacerbations Over the Study Treatment Period
eventArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Number of COPD Exacerbations Over the Study Treatment Period41105
SecondaryRescue Medication Use

The change from run-in period and daily during 52-week randomization treatment

Time frame:
Daily during 52-week randomization treatment
Reported as:
Mean · innhalation/day
Rescue Medication Use
innhalation/dayArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Rescue Medication Use-0.2 ± 1.00.0 ± 1.4
SecondaryHealth Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ)

The change from run-in period and daily during 52-week randomization treatment average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).

Time frame:
Daily during run-in period and daily 52-week randomization treatment
Reported as:
Mean · units on a scale
Health Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ)
units on a scaleArm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Health Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ)-2.03 ± 8.56-0.42 ± 7.47
SecondaryMorning Peak Expiratory Flow (PEF) Measured at Home

The change from Run-in period average to 52-week randomization Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily 52-week randomization treatment
Reported as:
Mean · Liter/minute(L/min)
Morning Peak Expiratory Flow (PEF) Measured at Home
Liter/minute(L/min)Arm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Morning Peak Expiratory Flow (PEF) Measured at Home5.9 ± 31.85.7 ± 30.9
SecondaryEvening Peak Expiratory Flow (PEF) Measured at Home

The change from Run-in period average to 52-week randomization Treatment period average for each treatment group

Time frame:
Daily during run-in period and daily 52-week randomization treatment
Reported as:
Mean · Liter/minute(L/min)
Evening Peak Expiratory Flow (PEF) Measured at Home
Liter/minute(L/min)Arm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Evening Peak Expiratory Flow (PEF) Measured at Home2.7 ± 30.05.2 ± 29.3
SecondaryMorning FEV1 Measured by the Subjects at Home

The change from run-in period and daily during 52-week randomization treatment

Time frame:
Daily during run-in period and daily 52-week randomization treatment
Reported as:
Mean · Liter(L)
Morning FEV1 Measured by the Subjects at Home
Liter(L)Arm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Morning FEV1 Measured by the Subjects at Home0.017 ± 0.1470.006 ± 0.171
SecondaryEvening FEV1 Measured by the Subjects at Home

The change from run-in period and daily during 52-week randomization treatment

Time frame:
Daily during run-in period and daily 52-week randomization treatment
Reported as:
Mean · Liter(L)
Evening FEV1 Measured by the Subjects at Home
Liter(L)Arm 1 - Symbicort TurbuhalerArm 2 - COPD Standard Therapy
Evening FEV1 Measured by the Subjects at Home0.006 ± 0.1420.010 ± 0.156

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symbicort Turbuhaler—25/130 (19.2%)75/130 (57.7%)
COPD Standard Therapy—34/130 (26.2%)72/130 (55.4%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventSymbicort TurbuhalerCOPD Standard Therapy
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders8/13020/130
PneumoniaRespiratory, thoracic and mediastinal disorders6/1305/130
Pneumonia BacterialRespiratory, thoracic and mediastinal disorders0/1305/130
CataractRespiratory, thoracic and mediastinal disorders0/1302/130
Cerebral InfarctionRespiratory, thoracic and mediastinal disorders2/1300/130
Lung Neoplasm MalignantRespiratory, thoracic and mediastinal disorders2/1301/130
Pulmonary TuberculosisRespiratory, thoracic and mediastinal disorders0/1302/130
BronchitisRespiratory, thoracic and mediastinal disorders1/1302/130
PneumothoraxRespiratory, thoracic and mediastinal disorders2/1300/130
Arteriosclerosis ObliteransRespiratory, thoracic and mediastinal disorders0/1301/130
Most frequent other events
Most frequent other events
EventSymbicort TurbuhalerCOPD Standard Therapy
NasopharyngitisInfections and infestations55/13051/130
BronchitisInfections and infestations15/13013/130
ConstipationGastrointestinal disorders10/13013/130
Back PainMusculoskeletal and connective tissue disorders6/13010/130
PneumoniaInfections and infestations9/1303/130
PharyngitisInfections and infestations9/1303/130
InsomniaPsychiatric disorders7/1301/130
DysphoniaRespiratory, thoracic and mediastinal disorders7/1301/130
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders7/1307/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Symbicort TurbuhalerCOPD Standard TherapyTotal
Mean70.1 (40 to 87)71.5 (54 to 85)70.8 (40 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)Symbicort TurbuhalerCOPD Standard TherapyTotal
Female549
Male125126251
08

Study locations

17 sites
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Toyota, Aichi, Japan
  • Research Site
    Yanagawa, Fukuoka, Japan
  • Research Site
    Asahikawa, Hokkaido, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Itami, Hyogo, Japan
  • Research Site
    Hitachi, Ibaraki, Japan
  • Research Site
    Tsukuba, Ibaraki, Japan
  • Research Site
    Sakaide, Kagawa, Japan
  • Research Site
    Fujisawa, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Koshi, Kumamoto, Japan
  • Research Site
    Shibata, Miyagi, Japan
  • Research Site
    Chuo, Tokyo, Japan
  • Research Site
    Setagaya, Tokyo, Japan
  • Research Site
    Hiroshima, Japan
  • Research Site
    Kyoto, Japan
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2010
First posted
Feb 18, 2010
Start
Jan 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Dec 5, 2013
Last update
Apr 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01070784
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 18, 2010
Start date
Jan 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Dec 5, 2013
Last update
Apr 29, 2014

Study contacts

Tomas Andersson, MD
study chair · AstraZeneca, R&D, Lund, Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

Start the discussion